Abstract
Eighty-one children seronegative for markers of hepatitis B virus infection aged 0-10 years received 10 micrograms of a yeast-based hepatitis B vaccine (Engerix B) at 0, 1, and 6 months. Eighty subjects responded with a geometric mean titre of 7640 IU/L one month after the third dose. All seroconverters produced high level of antibodies regardless of age, race, or sex. It is concluded that Engerix B used in the dose and schedule described is highly immunogenic.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigens / immunology*
-
Child
-
Child, Preschool
-
Female
-
Hepatitis B Antibodies / biosynthesis
-
Hepatitis B Surface Antigens / analysis
-
Hepatitis B Vaccines
-
Humans
-
Immunoenzyme Techniques
-
Infant
-
Male
-
Radioimmunoassay
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / immunology*
-
Viral Hepatitis Vaccines / adverse effects
-
Viral Hepatitis Vaccines / immunology*
Substances
-
Antigens
-
Hepatitis B Antibodies
-
Hepatitis B Surface Antigens
-
Hepatitis B Vaccines
-
Vaccines, Synthetic
-
Viral Hepatitis Vaccines